| June 3, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| Jun 2025Month disclosed | LIPFENDRA (enlicitide) | MRK | Topline readout | with hyperlipidemia | Positive | SEC Form 10-Q |
| May 26, 2025 | MK-6482 | MRK | PDUFA date | — | Scheduled | SEC Form 10-Q |
| May 22, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 21, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Colorectal Cancer | Completed | ClinicalTrials.gov |
| May 14, 2025 | WELIREG® (belzutifan) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 8, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Primary completion | Metastatic Esophageal Squamous Cell Carcinoma | Withdrawn | ClinicalTrials.gov |
| April 24, 2025 | — | MRK | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| April 21, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| April 15, 2025 | WELIREG® (belzutifan) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 19, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 4, 2025 | — | MRK | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| January 28, 2025 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| Jan 2025Month disclosed | WINREVAIR (sotatercept) | MRK | Interim readout | — | Positive | SEC Form 10-K |
| December 12, 2024 | Bridion (sugammadex sodium) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 11, 2024 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| Nov 2024Month disclosed | WINREVAIR (sotatercept) | MRK | Topline readout | — | Positive | SEC Form 10-K |
| September 26, 2024 | KEYTRUDA® (pembrolizumab) | MRK | Advisory committee | — | Completed | FDA advisory committee calendar |
| September 17, 2024 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 30, 2024 | Prevymis (letermovir) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 30, 2024 | Prevymis (letermovir) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 7, 2024 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 26, 2024 | Ohtuvayre (ensifentrine) | MRK | FDA approval | To treat chronic obstructive pulmonary disease | Approved | FDA Novel Drug Approvals |
| June 7, 2024 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 26, 2024 | Winrevair (sotatercept-csrk) | MRK | FDA approval | To treat pulmonary arterial hypertension | Approved | FDA Novel Drug Approvals |
| Mar 2024Month disclosed | generic | MRK | FDA approval | — | Approved | SEC Form 10-K |
| January 25, 2024 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 12, 2024 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 15, 2023 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 14, 2023 | WELIREG® (belzutifan) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 7, 2023 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| October 23, 2023 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| October 12, 2023 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| September 14, 2023 | Temodar (temozolomide) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 14, 2023 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 2, 2023 | Prevymis (letermovir) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 5, 2023 | Prevymis (letermovir) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 26, 2023 | Zinplava (bezlotoxumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 28, 2023 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 26, 2023 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| Jan 2023Month disclosed | Januvia (sitagliptin) | MRK | FDA approval | — | Approved | SEC Form 10-Q |
| December 16, 2022 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 20, 2022 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 2, 2022 | Fosaprepitant Dimeglumine (fosaprepitant dimeglumine) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 21, 2022 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 4, 2022 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 27, 2022 | Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 27, 2022 | Pifeltro (doravirine) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 17, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 9, 2021 | Zepatier (elbasvir; grazoprevir) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 3, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 17, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| October 13, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| September 17, 2021 | Steglujan (ertugliflozin; sitagliptin phosphate) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| September 17, 2021 | Segluromet (ertugliflozin; metformin hydrochloride) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| September 17, 2021 | Steglatro (ertugliflozin) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 31, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| August 13, 2021 | WELIREG® (belzutifan) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 10, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| July 21, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| July 1, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 25, 2021 | Bridion (sugammadex sodium) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 17, 2021 | Noxafil (posaconazole) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 31, 2021 | Noxafil (posaconazole) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 31, 2021 | Noxafil (posaconazole) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| May 5, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| March 16, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 22, 2021 | Bridion (sugammadex sodium) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 19, 2021 | Verquvo (vericiguat) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| December 4, 2020 | Januvia (sitagliptin) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| December 4, 2020 | Janumet (metformin hydrochloride; sitagliptin phosphate) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 13, 2020 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| October 14, 2020 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| October 2, 2020 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| July 14, 2020 | Isentress (raltegravir potassium) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 29, 2020 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 16, 2020 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 9, 2020 | Bridion (sugammadex sodium) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| June 4, 2020 | Recarbrio (cilastatin sodium; imipenem; relebactam) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| April 28, 2020 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 29, 2020 | Belsomra (suvorexant) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| January 8, 2020 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| July 16, 2019 | Recarbrio (cilastatin sodium; imipenem; relebactam) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 30, 2018 | Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 30, 2018 | Pifeltro (doravirine) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| December 19, 2017 | Steglujan (ertugliflozin; sitagliptin phosphate) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| December 19, 2017 | Segluromet (ertugliflozin; metformin hydrochloride) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| December 19, 2017 | Steglatro (ertugliflozin) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| November 8, 2017 | Prevymis (letermovir) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| October 21, 2016 | Zinplava (bezlotoxumab) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| January 28, 2016 | Zepatier (elbasvir; grazoprevir) | MRK | FDA approval | — | Approved | openFDA Drugs@FDA |
| June 28, 2013 | Belsomra (suvorexant) | MRK | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |